An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid
| dc.rights.license | open | en_US |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | DUPIN, Charles | |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | SUTTER, Jade | |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | AMINTAS, Samuel | |
| dc.contributor.author | DERIEPPE, Marie-Alix | |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | LALANNE, Magalie | |
| dc.contributor.author | COULIBALY, Soule | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | GUYON, Joris | |
| hal.structure.identifier | Institut de biochimie et génétique cellulaires [IBGC] | |
| dc.contributor.author | DAUBON, Thomas | |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | BOUTIN, Julian | |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | BLOUIN, Jean Marc | |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | RICHARD, Emmanuel | |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | MOREAU-GAUDRY, Francois | |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | BEDEL, Aurelie | |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | VENDRELY, Veronique | |
| hal.structure.identifier | BoRdeaux Institute in onCology [Inserm U1312 - BRIC] | |
| dc.contributor.author | DABERNAT, Sandrine | |
| dc.date.accessioned | 2022-10-26T10:05:22Z | |
| dc.date.available | 2022-10-26T10:05:22Z | |
| dc.date.issued | 2022-08-31 | |
| dc.identifier.issn | 2072-6694 (Print) 2072-6694 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/170119 | |
| dc.description.abstractEn | Radiosensitization of glioblastoma is a major ambition to increase the survival of this incurable cancer. The 5-aminolevulinic acid (5-ALA) is metabolized by the heme biosynthesis pathway. 5-ALA overload leads to the accumulation of the intermediate fluorescent metabolite protoporphyrin IX (PpIX) with a radiosensitization potential, never tested in a relevant model of glioblastoma. We used a patient-derived tumor cell line grafted orthotopically to create a brain tumor model. We evaluated tumor growth and tumor burden after different regimens of encephalic multifractionated radiation therapy with or without 5-ALA. A fractionation scheme of 5 × 2 Gy three times a week resulted in intermediate survival [48-62 days] compared to 0 Gy (15-24 days), 3 × 2 Gy (41-47 days) and, 5 × 3 Gy (73-83 days). Survival was correlated to tumor growth. Tumor growth and survival were similar after 5 × 2 Gy irradiations, regardless of 5-ALA treatment (RT group (53-67 days), RT+5-ALA group (40-74 days), HR = 1.57, p = 0.24). Spheroid growth and survival were diminished by radiotherapy in vitro, unchanged by 5-ALA pre-treatment, confirming the in vivo results. The analysis of two additional stem-like patient-derived cell lines confirmed the absence of radiosensitization by 5-ALA. Our study shows for the first time that in a preclinical tumor model relevant to human glioblastoma, treated as in clinical routine, 5-ALA administration, although leading to important accumulation of PpIX, does not potentiate radiotherapy. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Glioblastoma | |
| dc.subject.en | Radiotherapy | |
| dc.subject.en | 5-AminoLevulinic Acid (5-ALA) | |
| dc.subject.en | Protoporphyrin IX | |
| dc.subject.en | Radiodynamic therapy | |
| dc.title.en | An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3390/cancers14174244 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 36077783 | en_US |
| bordeaux.journal | Cancers | en_US |
| bordeaux.volume | 14 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 17 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.institution | CNRS | |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Institut National de la Santé et de la Recherche Médicale | en_US |
| bordeaux.identifier.funderID | Université de Bordeaux | en_US |
| bordeaux.identifier.funderID | Cancéropôle Grand Ouest | en_US |
| hal.identifier | hal-03830443 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-10-26T10:05:28Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancers&rft.date=2022-08-31&rft.volume=14&rft.issue=17&rft.eissn=2072-6694%20(Print)%202072-6694&rft.issn=2072-6694%20(Print)%202072-6694&rft.au=DUPIN,%20Charles&SUTTER,%20Jade&AMINTAS,%20Samuel&DERIEPPE,%20Marie-Alix&LALANNE,%20Magalie&rft.genre=article |
